GlassScriptPhysician profile
Benjamin C Akosa
NPI 1255427225
$10,648.87
in general payments reported to CMS, 2019-2025
30 companies · $1,269 in 2025
The $1,269 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,565 · 2020: $670 · 2021: $1,521 · 2022: $2,326 · 2023: $2,513 · 2024: $786 · 2025: $1,269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,567.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,415.75 | 2021-2025 | Vraylar |
| Alkermes, INC. | $1,226.92 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Janssen Pharmaceuticals, INC | $1,034.07 | 2019-2025 | Spravato, Invega Sustenna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $954.71 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $661.89 | 2019-2025 | Rexulti, Abilify Maintena |
| Lundbeck LLC | $660.70 | 2019-2025 | Rexulti, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $482.56 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $463.38 | 2019-2025 | Trintellix |
| Neurocrine Biosciences, INC. | $425.73 | 2019-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $393.29 | 2019-2024 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $381.38 | 2019-2025 | Austedo, Austedo Xr, Austedo Xr |
| Neos Therapeutics, LP | $349.45 | 2019-2023 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $339.97 | 2021-2025 | Qelbree, Qelbree |
| Axsome Therapeutics, INC. | $267.47 | 2023-2025 | Auvelity |
| Tris Pharma INC | $264.28 | 2020-2024 | Dyanavel Xr |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $262.79 | 2021-2025 | Azstarys |
| Allergan, INC. | $244.78 | 2019-2020 | |
| Bausch Health US, LLC | $137.42 | 2021-2024 | Aplenzin, Wellbutrin |
| Avanir Pharmaceuticals, INC. | $105.01 | 2019 | |
| Collegium Pharmaceutical, INC. | $89.92 | 2025 | Jornay Pm |
| E.R. Squibb & Sons, L.L.C. | $89.26 | 2024-2025 | Cobenfy |
| Noven Therapeutics, LLC | $70.79 | 2023-2024 | Xelstrym, Secuado |
| Vertical Pharmaceuticals, LLC | $68.26 | 2019-2020 | |
| Eisai INC. | $55.54 | 2021 | |
| Idorsia Pharmaceuticals US INC | $44.71 | 2022-2023 | Quviviq |
| Jazz Pharmaceuticals INC. | $41.64 | 2021 | |
| Adlon Therapeutics L.P. | $36.80 | 2019-2021 | |
| Shire North American Group INC | $34.06 | 2019 | |
| Vanda Pharmaceuticals INC. | $31.23 | 2020-2025 | Fanapt |
| Alfasigma USA, INC. | $15.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Akosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.